(Alemtuzumab)Biosimilar Reference Antibody-GS40017

货号：GS40017

Alemtuzumab is a humanized IgG1 monoclonal antibody targeting the cell surface glycoprotein CD52. It is approved for the treatment of relapsing-remitting multiple sclerosis and B-cell chronic lymphocytic leukemia. Its therapeutic mechanism involves rapid and profound depletion of circulating lymphocytes (T and B cells) and monocytes through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Following this "immune reset," a distinctive repopulation of the immune system occurs over months to years, which in MS is associated with long-term suppression of disease activity. Treatment requires careful monitoring due to significant risks, including serious infections and secondary autoimmune disorders.